HTG Medical, a Czech Republic-based medtech company, has announced that it has raised €450,000 in pre-seed funding while simultaneously securing EU Medical Device Regulation (MDR) certification for its flagship product, the HTG Urogram.
The funding round was led by Garage Angels, with participation from Electron Capital Partners, JIC Ventures, Jinej fond, and Dendis Capital. This investment marks a significant milestone for the company, which has now accumulated more than €1,000,000 in total funding since its establishment in 2019.
The HTG Urogram is an automated urine monitoring device designed for intensive care unit environments. The technology addresses a persistent challenge in critical care settings by automating manual monitoring tasks traditionally performed by nursing staff, thereby reducing workload while simultaneously improving measurement accuracy. The device represents a shift toward data-driven patient monitoring in hospital settings where precision and efficiency are paramount.
Regulatory Milestone Accelerates Market Entry
The attainment of EU MDR certification represents a crucial validation for the startup. This regulatory clearance demonstrates that the device meets stringent European safety and performance standards, enabling the company to pursue commercial deployment across EU member states. The timing of both the funding round and certification approval suggests the company is positioned to accelerate its market entry strategy.
According to Aleš Filipenský, Investment Director at Garage Angels, the investment decision reflected confidence in the company’s execution and business fundamentals. “The HTG Medical team blew us away by taking the Urogram from a rough hackathon concept to a certified product already active in patient care. The winning combination for us was a stellar founding team, clear MDR clearance, and a highly attractive recurring-revenue business model,” Filipenský stated.
The recurring-revenue model referenced in the investment thesis suggests HTG Medical is positioning the Urogram as a service-based offering rather than a one-time equipment sale, a strategy increasingly common in medical device startups seeking predictable revenue streams and stronger customer retention.
Expansion and Commercialization
The capital raised will be directed toward international expansion and the commercial launch of the HTG Urogram. This allocation indicates the company is moving beyond pilot phases and proof-of-concept deployments toward scaled market penetration. The focus on international expansion suggests ambitions extending beyond the Czech domestic market toward broader European healthcare systems.
The investment reflects growing investor interest in medical device solutions addressing operational inefficiencies within hospital environments. As European healthcare systems continue facing staffing pressures and resource constraints, technologies that enhance clinical efficiency while maintaining or improving care quality are attracting increased venture attention.
HTG Medical’s progression from concept to funded, certified startup exemplifies the maturation of Central Europe’s medtech ecosystem, where companies are increasingly attracting multinational investor interest and achieving regulatory milestones that position them for meaningful market impact.